PV Bulletin

Draft CVM GFI #256B - Compounding Animal Drugs from Bulk Drug Substances

The FDA has issued a draft guidance relating to the compounding of animal drugs from bulk drug substances, seeking public comments until November 27, 2026.

Primary source: Download the Draft Guidance Document

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA has introduced draft guidance for compounding animal drugs from bulk drug substances, detailing enforcement policies for federally-registered facilities under CGMP standards.

Why it matters

This guidance provides essential information on compliance for veterinary facilities, impacting how animal drugs are compounded and ensuring adherence to safety standards, thereby protecting animal health.

Action needed

Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 27, 2026

Full briefing

Practical implication

Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

The U.S. FDA has released a draft guidance document (CVM GFI #256B) on compounding animal drugs from bulk drug substances under current good manufacturing practices (CGMP) in federally-registered facilities. This draft is open for public comment and is not for implementation. Key aspects include compliance expectations for safety and quality standards in animal drug compounding.

What changed: The FDA has introduced draft guidance for compounding animal drugs from bulk drug substances, detailing enforcement policies for federally-registered facilities under CGMP standards.

Why it matters: This guidance provides essential information on compliance for veterinary facilities, impacting how animal drugs are compounded and ensuring adherence to safety standards, thereby protecting animal health.

Practical implication: Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

View original source

  • Source: FDA - Regulatory Information
  • Published at source: 2026-08-27T00:00:00.000Z
  • Discovered by monitor: 2026-08-27T22:07:17.026Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicEuropean Medicines Agency (EMA) · European Union · Updated Aug 27, 2026

New Restrictions on Antimicrobial Use in Veterinary Medicine

Urgency: High

Veterinary practitioners must now adjust their prescribing practices in accordance with the AMEG guidelines and monitor compliance with the new restrictions as outlined in the EMA's directive.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicNational Pharmaceutical Regulatory Agency (NPRA), Malaysia · Malaysia · Updated Aug 25, 2026

List of Cosmetic Manufacturers in QUEST System in Malaysia

Urgency: High

Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Aug 26, 2026

Monthly Reporting of Medicines Under Evaluation by EMA

Monitoring

Update internal systems and workflows to integrate monthly Excel reports from EMA starting March 2025, ensuring timely capture of information on medicines under evaluation and any extension applications.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicTGA · Australia · Updated Aug 25, 2026

Additional Public Consultation on Amending the Poisons Standard regarding Ethylene Oxide, Propylene Oxide, and Epichlorohydrin

Monitoring

Regulatory Intelligence leads should initiate monitoring of feedback and prepare for potential regulatory adjustments related to the specified substances.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward